It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Acute Myeloid Leukemia Treatment Study

Clinical Trial Title: 
Expanded access of cytarabine:daunorubicin liposome injection for patients 60-75 years of age with secondary AML.
Clinical Trial Protocol ID: 
15081001
Clinical Trial Investigator Name: 
Melissa L. Larson, MD
Clinical Trial Protocol Description: 

To provide cytarabine:daunorubicin liposome injection treatment for patients 60-75 years of age with newly diagnosed secondary AML and to collect additional data on treatment safety.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are age 60-75 years.
  • Have a new diagnosis of AML.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a diagnosis of APL.
  • Have had any major surgery within the last 4 weeks.
  • Have kidney or liver diseases.
  • Have any copper-metabolism disorder.
  • Have heart failure.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-1346
Contact Name: 
Kimberly Koetter RN, BS, OCN